Keyword: Recurrence
2 results found.
Congress Abstract
Oncology, Nuclear Medicine and Transplantology, 2(3, Suppl. 1), 2026, onmt_A37, https://doi.org/10.63946/onmt/19300
ABSTRACT:
Introduction: Papillary thyroid cancer (PTC) is characterized by a favorable prognosis; however, disease recurrence remains a clinically significant problem among adolescent and young adult (AYA) patients. The prognostic role of molecular alterations in this age group remains insufficiently studied, especially in Central Asian populations.
Objective: To evaluate clinical-pathological and molecular factors associated with PTC recurrence in young adult patients from Kazakhstan.
Materials and Methods: This retrospective multicenter study included 246 patients with histologically confirmed PTC. Tumor tissue samples obtained between 2016 and 2020 were collected at three specialized oncology centers in Kazakhstan: the Kazakh Institute of Oncology and Radiology (Almaty), the Center for Nuclear Medicine and Oncology (Semey), and the Multidisciplinary Center of Oncology and Surgery (Ust-Kamenogorsk). Clinical-pathological characteristics and molecular genetic alterations were analyzed in relation to recurrence risk and survival outcomes. Multivariate regression analysis and time-to-event methods were used to identify factors associated with recurrence, progression-free survival (PFS), and overall survival (OS).
Results: In the AYA subgroup, none of the evaluated clinical-pathological or molecular factors retained a statistically significant association with recurrence after multivariate adjustment. TERT promoter alterations demonstrated the largest estimated association with recurrence (odds ratio [OR] 9.05; 95% confidence interval [CI] 1.00–59.86; p = 0.333); however, statistical significance was not reached. In the overall cohort, the presence of lymph node metastases demonstrated the most pronounced trend toward worse PFS (hazard ratio [HR] 9.61; 95% CI 0.92–100.49; p = 0.059). No statistically significant clinical-pathological or molecular predictors of overall survival were identified.
Conclusions: The risk of PTC recurrence in young adult patients is characterized by heterogeneity and cannot be fully assessed based on clinical-pathological factors alone. TERT promoter alterations may have potential prognostic significance. Larger prospective studies in the Central Asian population are needed to clarify the role of molecular markers and improve individual risk stratification.
Objective: To evaluate clinical-pathological and molecular factors associated with PTC recurrence in young adult patients from Kazakhstan.
Materials and Methods: This retrospective multicenter study included 246 patients with histologically confirmed PTC. Tumor tissue samples obtained between 2016 and 2020 were collected at three specialized oncology centers in Kazakhstan: the Kazakh Institute of Oncology and Radiology (Almaty), the Center for Nuclear Medicine and Oncology (Semey), and the Multidisciplinary Center of Oncology and Surgery (Ust-Kamenogorsk). Clinical-pathological characteristics and molecular genetic alterations were analyzed in relation to recurrence risk and survival outcomes. Multivariate regression analysis and time-to-event methods were used to identify factors associated with recurrence, progression-free survival (PFS), and overall survival (OS).
Results: In the AYA subgroup, none of the evaluated clinical-pathological or molecular factors retained a statistically significant association with recurrence after multivariate adjustment. TERT promoter alterations demonstrated the largest estimated association with recurrence (odds ratio [OR] 9.05; 95% confidence interval [CI] 1.00–59.86; p = 0.333); however, statistical significance was not reached. In the overall cohort, the presence of lymph node metastases demonstrated the most pronounced trend toward worse PFS (hazard ratio [HR] 9.61; 95% CI 0.92–100.49; p = 0.059). No statistically significant clinical-pathological or molecular predictors of overall survival were identified.
Conclusions: The risk of PTC recurrence in young adult patients is characterized by heterogeneity and cannot be fully assessed based on clinical-pathological factors alone. TERT promoter alterations may have potential prognostic significance. Larger prospective studies in the Central Asian population are needed to clarify the role of molecular markers and improve individual risk stratification.
Congress Abstract
Oncology, Nuclear Medicine and Transplantology, 2(3, Suppl. 1), 2026, onmt_A18, https://doi.org/10.63946/onmt/19255
ABSTRACT:
Introduction: Colorectal cancer remains one of the leading causes of cancer morbidity and mortality. Timely detection of metastases and assessment of treatment efficacy are important tasks in modern oncology. PET/CT with 18F-FDG has limitations related to physiological uptake of the radiopharmaceutical in the intestine and variable sensitivity across different histological tumor types. The use of 68Ga-FAPI, which has high affinity for tumor stroma and low background uptake, is a promising alternative.
Objective: To evaluate the diagnostic value of PET/CT with 68Ga-FAPI in detecting colorectal cancer metastases and monitoring treatment efficacy.
Materials and Methods: The study included 311 patients with histologically verified colorectal cancer examined between January 2024 and January 2026. The study had a retrospective-prospective design. All patients underwent PET/CT using 68Ga-FAPI. Radiopharmaceutical distribution, the presence of metastatic and additional suspicious lesions, as well as dynamic changes during treatment were assessed. Statistical analysis was performed in Microsoft Excel, calculating mean, median, and SUVmax range. The study was approved by the Local Bioethics Committee of the "Astana Medical University" NJSC (Decision No. 11 dated 27.02.2026).
Results: The mean age of patients was 58.5 years (range 17–87 years); 171 (55.0%) were women and 140 (45.0%) were men. Adenocarcinoma predominated (87%), predominantly G2; the majority of patients had stage II–III disease. Metastases were detected in 31.2% of patients, most frequently in the liver and lymph nodes; recurrence was observed in 13.0%. Additional suspicious lesions requiring verification were identified in 40% of patients. The mean SUVmax of metastatic lesions was 6.46 (range 1.1–13.8), for recurrence – 5.78 (range 2.6–9.5), and for suspicious lesions – 4.02.
Conclusions: PET/CT using 68Ga-FAPI is a promising imaging modality for colorectal cancer, allowing detection of metastatic and additional suspicious lesions and assessment of dynamic changes during antitumor treatment.
Objective: To evaluate the diagnostic value of PET/CT with 68Ga-FAPI in detecting colorectal cancer metastases and monitoring treatment efficacy.
Materials and Methods: The study included 311 patients with histologically verified colorectal cancer examined between January 2024 and January 2026. The study had a retrospective-prospective design. All patients underwent PET/CT using 68Ga-FAPI. Radiopharmaceutical distribution, the presence of metastatic and additional suspicious lesions, as well as dynamic changes during treatment were assessed. Statistical analysis was performed in Microsoft Excel, calculating mean, median, and SUVmax range. The study was approved by the Local Bioethics Committee of the "Astana Medical University" NJSC (Decision No. 11 dated 27.02.2026).
Results: The mean age of patients was 58.5 years (range 17–87 years); 171 (55.0%) were women and 140 (45.0%) were men. Adenocarcinoma predominated (87%), predominantly G2; the majority of patients had stage II–III disease. Metastases were detected in 31.2% of patients, most frequently in the liver and lymph nodes; recurrence was observed in 13.0%. Additional suspicious lesions requiring verification were identified in 40% of patients. The mean SUVmax of metastatic lesions was 6.46 (range 1.1–13.8), for recurrence – 5.78 (range 2.6–9.5), and for suspicious lesions – 4.02.
Conclusions: PET/CT using 68Ga-FAPI is a promising imaging modality for colorectal cancer, allowing detection of metastatic and additional suspicious lesions and assessment of dynamic changes during antitumor treatment.